Table 4 Associationsa between adipokines and breast cancer specific mortality and risk of recurrence stratified by hormone receptor status.

From: Association of circulating leptin, adiponectin, and resistin concentrations with long-term breast cancer prognosis in a German patient cohort

N/events

Breast cancer specific mortality

Risk of recurrence

ERPR positive

 

ERPR negative

 

ERPR positive

 

ERPR negative

 

2,311/259

 

390/78

 

2227/328

 

369/91

 

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

Leptin continuous

0.94 (0.85, 1.04)

0.21

0.93 (0.77, 1.11)

0.43

1.01 (0.92, 1.10)

0.83

0.91 (0.75, 1.09)

0.30

Baseline quintilesb (ng/ml)

        

 < 1.82

Reference

 

Reference

 

Reference

 

Reference

 

 < 3.47

0.96 (0.65, 1.42)

 

1.24 (0.61, 2.52)

 

0.73 (0.50, 1.06)

 

0.85 (0.44, 1.64)

 

 < 5.98

0.75 (0.49, 1.16)

 

1.28 (0.58, 2.81)

 

1.12 (0.79, 1.60)

 

0.73 (0.34, 1.58)

 

 < 10.66

0.88 (0.57, 1.35)

 

1.16 (0.48, 2.79)

 

0.97 (0.66, 1.43)

 

0.70 (0.29, 1.68)

 

10.66 + 

0.98 (0.62, 1.57)

 

0.72 (0.28, 1.89)

 

1.14 (0.75, 1.72)

 

0.50 (0.20, 1.21)

 

Adiponectin continuous

0.89 (0.77, 1.03)

0.11

1.37 (1.04, 1.80)

0.03

1.05 (0.92, 1.20)

0.51

1.15 (0.88, 1.49)

0.32

Baseline quintiles b (mg/l)

        

 < 14.95

Reference

 

Reference

 

Reference

 

Reference

 

 < 21.26

0.76 (0.50, 1.15)

 

1.38 (0.55, 3.48)

 

1.09 (0.76, 1.57)

 

1.57 (0.68, 3.62)

 

 < 28.14

0.90 (0.61, 1.34)

 

1.96 (0.81, 4.72)

 

1.08 (0.74, 1.59)

 

1.57 (0.72, 3.44)

 

 < 39.31

0.90 (0.60, 1.35)

 

2.07 (0.89, 4.81)

 

1.28 (0.89, 1.84)

 

1.39 (0.64, 3.05)

 

39.31 + 

0.84 (0.57, 1.25)

 

2.51 (1.07, 5.92)

 

1.18 (0.82, 1.71)

 

1.21 (0.52, 2.82)

 

Resistin continuous

0.93 (0.83, 1.05)

0.25

1.18 (0.93, 1.50)

0.18

0.92 (0.82, 1.03)

0.14

1.04 (0.82, 1.33)

0.75

Baseline quintiles b (ng/ml)

        

 < 7.87

Reference

 

Reference

 

Reference

 

Reference

 

 < 12.57

0.77 (0.46, 1.28)

 

1.81 (0.65, 5.01)

 

1.15 (0.74, 1.69)

 

1.05 (0.42, 2.67)

 

 < 19.09

1.18 (0.74, 1.89)

 

1.67 (0.62, 4.56)

 

0.86 (0.57, 1.31)

 

1.68 (0.74, 3.81)

 

 < 31.39

0.79 (0.49, 1.28)

 

1.24 (0.44, 3.51)

 

0.73 (0.48, 1.11)

 

1.02 (0.43, 1.42)

 

31.39 + 

0.89 (0.55, 1.39)

 

2.31 (0.87, 6.08)

 

0.80 (0.53, 1.20)

 

1.36 (0.58, 3.21)

 
  1. aModels were adjusted for the other adipokines, BMI, region, age at diagnosis, time between diagnosis and first blood draw, timing of blood draw in relation to chemotherapy, tumor size, nodal status, metastasis, grading, ERPR one or both positive, previous tumors, MHT use, leisure time PA at age 50 (quintiles of MET x h/wk), mode of detection by imaging (yes/no), combined Her2 receptor status/trastuzumab use, radiotherapy, tamoxifen and/or aromatase inhibitor.
  2. bQuintiles were derived from baseline measurements. FU measurements were categorized into respective baseline quintiles.
  3. ERPR estrogen receptor/progesterone receptor.
Back to article page